Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|March 12, 2014

Almac Expands Asia Pacific Operations

Almac expands technical, project, and operational resources in Asia.

Almac

reported the expansion of its clinical services and technologies capabilities to include technical, project, and operational resources in Asia. The company has established regional hubs in Singapore and Japan to improve the need to conduct clinical trials in Asia and manage global trials from the region.

As part of the expansion, Almac is building a new secondary packaging facility in Singapore, which is expected to open by the end of 2014.

Source:

Almac


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.